Literature DB >> 6508862

Increased von Willebrand factor antigen in the plasma of patients with vasculitis.

S R Nusinow, A B Federici, T S Zimmerman, J G Curd.   

Abstract

The plasma concentrations of von Willebrand factor antigen (vWF:Ag) were determined in 101 patients who had the following diagnoses: vasculitis 8 patients, systemic lupus erythematosus (SLE) 51, rheumatoid arthritis (RA) 28, asthma 7, hereditary angioedema 7. The greatest mean concentration of vWF:Ag, 469% (normal 100% +/- 50), was observed in patients with vasculitis, often without elevation of the erythrocyte sedimentation rate. The mean concentration of vWF:Ag was also increased in both SLE (277%) and RA (194%). Twenty-four patients (15 with SLE, 6 with vasculitis, 3 with RA) had vWF:Ag concentrations greater than 300%. Four of these patients died within 1 year of the date of the study. Of the 15 SLE patients, 9 had vasculitis and 2 had active glomerulonephritis. The 3 RA patients had severe disease associated with extraarticular manifestations. Elevated vWF:Ag may reflect vascular damage, while markedly elevated levels of vWF:Ag appear to indicate a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508862     DOI: 10.1002/art.1780271211

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

1.  Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.

Authors:  A Uddhammar; S Rantapåå-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

2.  Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies.

Authors:  C O Savage; B E Pottinger; G Gaskin; C M Lockwood; C D Pusey; J D Pearson
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

3.  Markers of vascular perturbation correlate with airway structural change in asthma.

Authors:  Mats W Johansson; Stanley J Kruger; Mark L Schiebler; Michael D Evans; Ronald L Sorkness; Loren C Denlinger; William W Busse; Nizar N Jarjour; Robert R Montgomery; Deane F Mosher; Sean B Fain
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

4.  Circulating adhesion molecules ICAM-1, E-selectin, and von Willebrand factor in Henoch-Schönlein purpura.

Authors:  O Söylemezoglu; N Sultan; T Gursel; N Buyan; E Hasanoglu
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

5.  Von Willebrand factor in the outcome of temporal arteritis.

Authors:  M C Cid; J Monteagudo; J Oristrell; J Vilaseca; L Pallarés; R Cervera; C Font; J Font; M Ingelmo; A Urbano-Márquez
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

6.  Roles of claudin-5 and von Willebrand factor in patients with rheumatoid arthritis.

Authors:  Gönül Gurol; Ihsan Hakkı Ciftci; Halil Harman; Engin Karakece; Ayhan Kamanli; Ibrahim Tekeoglu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

7.  Anti-endothelial cell antibody, thrombomodulin, and von Willebrand factor in idiopathic inflammatory myopathies.

Authors:  K V Salojin; A Bordron; E L Nassonov; V Z Shtutman; N G Guseva; A A Baranov; I N Targoff; P Youinou
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

8.  Factor VIII related antigen in the assessment of vasculitis.

Authors:  A D Woolf; G Wakerley; T B Wallington; D G Scott; P A Dieppe
Journal:  Ann Rheum Dis       Date:  1987-06       Impact factor: 19.103

9.  Von Willebrand factor antigen in assessment of vasculitis in patients with connective tissue diseases.

Authors:  J Kloczko; A Kuryliszyn-Moskal; K Bernacka; M Bielawiec; B Cylwik; P Radziwon
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

10.  Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis.

Authors:  C S Lau; M McLaren; J Hanslip; M Kerr; J J Belch
Journal:  Ann Rheum Dis       Date:  1993-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.